Innate Pharma

News

New data at EHA backs Sanofi, Innate’s NK cell engager

One of the lead candidates in Sanofi natural killer (NK) cell engager alliance with Innate Pharma has shown encouraging and durable efficacy in various haematological cancers, according to

News

BioNTech and Takeda add new ADCs to their pipelines

A pair of licensing deals today for BioNTech and Takeda provide further examples that antibody-drug conjugates (ADCs) are cementing their place as in the biopharma armamen

News

AZ, Innate's checkpoint inhibitor monalizumab flunks phase 3...

AstraZeneca has abandoned a phase 3 trial of its experimental immuno-oncology candidate monalizumab in head and neck cancer, after an interim analysis suggested it was unlikely to show a be

Views & Analysis

Can in vivo imaging deliver the full potential of immunotherapy

The next generation of immunotherapy? Innate Pharma targets ...

Clinical-stage oncology biotech Innate Pharma is on a mission to harness the power of natural killer cells to fight cancer.

News

Innate Pharma gains rights to AZ's recently approved leukaem...

France’s Innate Pharma has gained rights to AstraZeneca's recently approved leukaemia drug Lumoxiti, in a deal that expands a collaboration that began more than three years ago.

News